These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 15183345

  • 1. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets.
    Ohtaka H, Muzammil S, Schön A, Velazquez-Campoy A, Vega S, Freire E.
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1787-99. PubMed ID: 15183345
    [Abstract] [Full Text] [Related]

  • 2. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H, Freire E.
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [Abstract] [Full Text] [Related]

  • 3. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H, Schön A, Freire E.
    Biochemistry; 2003 Nov 25; 42(46):13659-66. PubMed ID: 14622012
    [Abstract] [Full Text] [Related]

  • 4. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.
    Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623
    [Abstract] [Full Text] [Related]

  • 5. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
    Velazquez-Campoy A, Kiso Y, Freire E.
    Arch Biochem Biophys; 2001 Jun 15; 390(2):169-75. PubMed ID: 11396919
    [Abstract] [Full Text] [Related]

  • 6. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 7. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
    Böttcher J, Blum A, Heine A, Diederich WE, Klebe G.
    J Mol Biol; 2008 Nov 07; 383(2):347-57. PubMed ID: 18692068
    [Abstract] [Full Text] [Related]

  • 8. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E, Samudrala R.
    Antivir Ther; 2005 Nov 07; 10(1):157-66. PubMed ID: 15751773
    [Abstract] [Full Text] [Related]

  • 9. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
    Cihlar T, He GX, Liu X, Chen JM, Hatada M, Swaminathan S, McDermott MJ, Yang ZY, Mulato AS, Chen X, Leavitt SA, Stray KM, Lee WA.
    J Mol Biol; 2006 Oct 27; 363(3):635-47. PubMed ID: 16979654
    [Abstract] [Full Text] [Related]

  • 10. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.
    J Biomol Struct Dyn; 2005 Jun 27; 22(6):615-24. PubMed ID: 15842167
    [Abstract] [Full Text] [Related]

  • 11. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V.
    J Chem Inf Model; 2009 Jul 27; 49(7):1751-61. PubMed ID: 19537723
    [Abstract] [Full Text] [Related]

  • 12. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H, Velázquez-Campoy A, Xie D, Freire E.
    Protein Sci; 2002 Aug 27; 11(8):1908-16. PubMed ID: 12142445
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S, Shah K.
    In Silico Biol; 2008 Aug 27; 8(5-6):427-47. PubMed ID: 19374129
    [Abstract] [Full Text] [Related]

  • 14. Genotype dependent QSAR for HIV-1 protease inhibition.
    Boutton CW, De Bondt HL, De Jonge MR.
    J Med Chem; 2005 Mar 24; 48(6):2115-20. PubMed ID: 15771454
    [Abstract] [Full Text] [Related]

  • 15. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G, MASTER Cohort GenPheRex Study Group, MASTER Cohort PhenGen Study Group.
    J Med Virol; 2004 Sep 24; 74(1):29-33. PubMed ID: 15258965
    [Abstract] [Full Text] [Related]

  • 16. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M, Bray J, Rezácová P, Sasková K, Brynda J, Pokorná J, Mammano F, Rulísek L, Konvalinka J.
    J Mol Biol; 2007 Dec 07; 374(4):1005-16. PubMed ID: 17977555
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S, Kairys V, Fernandes MX, Schiffer C, Gilson MK.
    Proteins; 2007 Aug 01; 68(2):561-7. PubMed ID: 17474129
    [Abstract] [Full Text] [Related]

  • 18. Protease inhibition in African subtypes of HIV-1.
    Velázquez-Campoy A, Vega S, Fleming E, Bacha U, Sayed Y, Dirr HW, Freire E.
    AIDS Rev; 2003 Aug 01; 5(3):165-71. PubMed ID: 14598565
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC, Robbins A, Graña P, Paleo MR, Correa JF, Villaverde MC, Sardina FJ, Govindasamy L, Agbandje-McKenna M, McKenna R, Dunn BM, Sussman F.
    J Med Chem; 2008 Feb 28; 51(4):852-60. PubMed ID: 18215016
    [Abstract] [Full Text] [Related]

  • 20. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Hou T, Yu R.
    J Med Chem; 2007 Mar 22; 50(6):1177-88. PubMed ID: 17300185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.